An observational study in Pachychoroid Disease, sponsored by Singapore National Eye Centre. Recruiting at 4 sites in 3 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Singapore National Eye Centre · Observational
This study is about understanding how a condition called pachychoroid changes over time. Pachychoroid refers to an anatomic choroidal characteristic with abnormally thick choroid or abnormally dilated Haller's vessels. Pachychoroid can range from mild forms which does not cause any problems to more serious ones that might cause vision loss.This study will recruit participants with pachychoroid, to learn more about how this condition develops, how it affects people in the long run, and what factors might make it worse.
This study aims to document the longitudinal progression pattern and the incidence rate of progression of choroidal venous alteration (defined as either an increase in number of quadrants with pachyvessels or formation of new anastomoses which violates the physiological watershed It will provide valuable natural history data to study the pattern of evolution of choroidal vessels over time and validate the proposed multi-hit theory over a period of three years.
Singapore National Eye Centre is the lead sponsor of 87 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will aim to recruit 170 participants in Singapore National Eye Centre (SNEC) and 50 participants in National University Hospital, 30 participants from the University of Malaya
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression of choroidal venous alterations
Proportion of eyes demonstrating progression of choroidal venous alterations, defined as either an increase in number of quadrants with pachyvessels or formation of new choroidal anastomoses.
Time frame: 3 years
Incidence of progression of pachychoroid disease manifestation
New onset of Central Serous Chorioretinopathy (CSCR), focal Retinal Pigment Epithelium (RPE) changes, or other pachychorois related findings.
Time frame: 3 years
Risk factors associated with progression of choroidal venous alteration
Assessment of demographic, cilinical, and imaging parameters associated with progression.
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Singapore National Eye Centre